These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9338469)

  • 1. Alpha-1 acid glycoprotein is an immunosuppressive factor found in ascites from ovaria carcinoma.
    Elg SA; Mayer AR; Carson LF; Twiggs LB; Hill RB; Ramakrishnan S
    Cancer; 1997 Oct; 80(8):1448-56. PubMed ID: 9338469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification and characterization of an immunosuppressive factor from ovarian cancer ascites fluid.
    Oh SK; Moolten FL
    Eur J Immunol; 1981 Oct; 11(10):780-8. PubMed ID: 6273181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
    Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
    Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites: radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity.
    Holm J; Hansen SI; Høier-Madsen M; Birn H; Helkjaer PE
    Arch Biochem Biophys; 1999 Jun; 366(2):183-91. PubMed ID: 10356282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.
    Loercher AE; Nash MA; Kavanagh JJ; Platsoucas CD; Freedman RS
    J Immunol; 1999 Dec; 163(11):6251-60. PubMed ID: 10570318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.
    Xu Y; Gaudette DC; Boynton JD; Frankel A; Fang XJ; Sharma A; Hurteau J; Casey G; Goodbody A; Mellors A
    Clin Cancer Res; 1995 Oct; 1(10):1223-32. PubMed ID: 9815916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
    Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
    Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
    Runnebaum IB; Brüning A
    Clin Cancer Res; 2005 Sep; 11(17):6325-32. PubMed ID: 16144937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
    Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
    Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocyte membrane alpha-1-acid glycoprotein: a cellular synthesis during lymphocyte activation.
    Stefanini GF; Mazzetti M; Piccinini GC; Capelli S; Baraldini M; Gasbarrini G
    Biochem Int; 1989 Aug; 19(2):397-403. PubMed ID: 2684161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of alpha-AR subtypes in T lymphocytes and role of the alpha-ARs in mediating modulation of T cell function.
    Bao JY; Huang Y; Wang F; Peng YP; Qiu YH
    Neuroimmunomodulation; 2007; 14(6):344-53. PubMed ID: 18463421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary study on fusions of ovarian carcinoma cells to dendritic cell transfected with interleukin-12 gene in vitro].
    Peng P; Shen K; He W; Wu M; Wei W; Lang JH; Zhang SM; Qi J; Hu Y; Zhao JQ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):57-61. PubMed ID: 16635331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.
    Olt G; Berchuck A; Soisson AP; Boyer CM; Bast RC
    Cancer; 1992 Oct; 70(8):2137-42. PubMed ID: 1394043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
    Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.